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Global, site-specific analysis of 
neuronal protein S-acylation
Mark O. Collins  1,2, Keith T. Woodley2 & Jyoti S. Choudhary1
Protein S-acylation (palmitoylation) is a reversible lipid modification that is an important regulator 
of dynamic membrane-protein interactions. Proteomic approaches have uncovered many putative 
palmitoylated proteins however, methods for comprehensive palmitoylation site characterization 
are lacking. We demonstrate a quantitative site-specific-Acyl-Biotin-Exchange (ssABE) method that 
allowed the identification of 906 putative palmitoylation sites on 641 proteins from mouse forebrain. 
62% of sites map to known palmitoylated proteins and 102 individual palmitoylation sites are known 
from the literature. 54% of palmitoylation sites map to synaptic proteins including many GPCRs, 
receptors/ion channels and peripheral membrane proteins. Phosphorylation sites were also identified 
on a subset of peptides that were palmitoylated, demonstrating for the first time co-identification 
of these modifications by mass spectrometry. Palmitoylation sites were identified on over half of the 
family of palmitoyl-acyltransferases (PATs) that mediate protein palmitoylation, including active 
site thioester-linked palmitoyl intermediates. Distinct palmitoylation motifs and site topology were 
identified for integral membrane and soluble proteins, indicating potential differences in associated PAT 
specificity and palmitoylation function. ssABE allows the global identification of palmitoylation sites as 
well as measurement of the active site modification state of PATs, enabling palmitoylation to be studied 
at a systems level.
Protein S-palmitoylation, also known as S-acylation, is a thioester linkage of a lipid to cysteine residues in pro-
teins, with the 16-carbon fatty acid palmitate being the most common type. Palmitoylation is the only known 
reversible lipid modification of proteins and can therefore act as a regulatory post-translational modification. 
Proteins can be palmitoylated by a family of 23 mammalian palmitoyl-acyltransferases (PATs) that contain 
DHHC domains, the catalytic domain of these enzymes containing a conserved “DHHC” sequence motif with 
the cysteine residue carrying a thioester linked palmitoyl intermediate that is transferred to substrate proteins1. 
Proteins are depalmitoylated by two cytosolic acyl-protein thioesterases2, 3 (APT1 and APT2), PPT14 and a 
recently discovered family of ABHD17 proteins5.
Palmitoylation increases hydrophobicity at specific points in protein structures that allow tethering/interac-
tion of proteins to membranes, a process that can regulate protein trafficking, compartmentalization and cell sur-
face expression. Classic examples of soluble proteins that associate with membranes through palmitoylation are 
Ras6 and PSD-957. Integral membrane proteins are also widely regulated by palmitoylation; controlling for exam-
ple trafficking of receptors to the plasma membrane as well as their internalization when no longer required at the 
cell surface. Palmitoylation can also regulate the topology/structure of integral membrane proteins by for example 
tethering cytoplasmic tails to the membrane and there by masking or indeed creating sites for interacting proteins 
to bind as well as regulating the accessibility of protein domains to enzymes that mediate other regulatory PTMs8.
The characterization of palmitoylated proteins on a proteome scale has been accelerated by the development 
of purification methods that selectively replace palmitoyl groups with affinity purification tags9 or metabolic 
labelling10 with palmitic acid analogues that are selectively captured. Acyl-biotin exchange (ABE)11 was adapted 
by Davis and co-workers12 for proteomic applications and involves blocking all free cysteines in proteins, sub-
sequent release of palmitoyl thioester bonds using hydroxylamine at neutral pH11 and biotinylation of newly 
exposed cysteine thiol groups. Labelled proteins can then be purified using streptavidin resin and identified using 
LC-MS/MS analysis. The second approach developed by Hang and co-workers13 and subsequently by Martin 
and Cravatt10 involves metabolic labelling of cells with bio-orthogonal probes of palmitoylation. The palmitic 
acid analogue 17-ODYA is incorporated into proteins at sites of palmitoylation and click-chemistry is used to 
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specifically label 17-OYDA modified proteins with biotin which can be used to purify proteins palmitoylated 
during the period of metabolic labelling for characterization by LC-MS/MS analysis. Both ABE and click chem-
istry based approaches can be combined with quantitative proteomic workflows to enable relative quantification 
of palmitoylated proteins compared to appropriate controls as well as relative levels of palmitoylated proteins in 
perturbation experiments14.
The combination of these enrichment methods with mass spectrometry has enabled the identification of many 
palmitoylated proteins from a range of cells, tissues and species9, 10, 14–16. Global palmitoyl-proteome analysis has 
shown that this modification is relatively common and occurs on proteins involved in a range of biological pro-
cesses. However, such approaches lack the resolution to identify exact sites of palmitoylation, the number of pal-
mitoylation sites on a given protein or the potential to measure differentially regulated palmitoylation sites which 
is an extra level of complexity that is emerging in the field17, 18. Recently, attempts have been made to develop pro-
teomic approaches that generate site specific data. Yang and co-workers adapted the ABE method by performing 
free cysteine blocking, hydroxylamine treatment and biotin labelling steps in a similar manner as the standard 
method but next performed tryptic digestion and purified biotinylated peptides using streptavidin resin19. Eluted 
peptides were analyzed by LC-MS/MS analysis and the relative enrichment of peptides in hydroxylamine treated 
compared to control samples was assessed by spectral counting. 25 known and 143 candidate palmitoylation 
sites were reported, however, the confidence in palmitoylation site identification was uncertain due to the type 
of quantification employed. Recently, an alternative approach involving resin assisted capture (acyl-RAC) was 
developed by Forrester and co-workers to identify sites of S-acylation20. In this strategy, the biotin/avidin purifi-
cation step is replaced by capture of previously palmitoylated cysteine thiols on a thiol-reactive resin and protein 
digestion is performed on-resin. This approach allowed the identification of 84 peptides containing putative sites 
of S-acylation but quantification of enrichment of these peptides in hydroxylamine treated compared to control 
samples was not reported.
In order to build upon and extend the scope of these approaches, we have developed a modified peptide-centric 
version of acyl-biotin exchange designated ssABE (site-specific Acyl-Biotin Exchange), in which most of the pro-
tocol is performed in a single reaction chamber in a fraction of the time as the traditional acyl-biotin exchange 
method, allowing it to be used as a site-specific palmitoylation assay.
Results and Discussion
ssABE-a strategy for mapping palmitoylation sites in endogenous proteins. The standard ABE 
method involves eight chloroform-methanol precipitation steps to remove reduction/alkylation reagents and biotin9  
which make it a lengthy procedure and also results in significant protein loss. Centrifugal molecular weight-based 
cut-off concentrators are now commonly used for sample clean-up and proteolytic digestion21 and more recently 
for enrichment of post-translational modifications22. We extracted protein from adult mouse forebrain samples in 
a high SDS-containing buffer in order to maximize recovery of integral membrane proteins, which also contains 
TCEP and iodoacetamide for concurrent disulfide bond reduction and cysteine alkylation. Reduced and alkylated 
protein samples are then buffer exchanged using 8 M urea in a centrifugal concentrator. Critically, sample clean-up, 
hydroxylamine treatment, biotin labelling of previously palmitoylated cysteines, biotin removal and tryptic diges-
tion steps are all performed in the same chamber of the concentrator to minimize sample loss and to greatly increase 
the speed in which the method can be performed (Fig. 1). After tryptic digestion, samples are removed from the 
chamber and incubated with streptavidin resin. Stringent washes are performed to remove non-specifically bound 
peptides and biotinylated peptides are selectively released by virtue of TCEP cleavable HPDP-biotin. Eluted pep-
tides are acidified and analyzed by LC-MS/MS and unmodified cysteine resides in peptides quantitatively enriched 
in hydroxylamine treated compared to control samples are indicative of palmitoylation sites.
The fully optimized ssABE method was used to label and purify palmitoylated peptides from six biological 
replicates each of hydroxylamine treated and control mouse forebrain lysates. Peptides from each purification 
were analyzed in duplicate by LC-MS/MS. Data was analyzed with MaxQuant23 and quantitation performed 
using peptide intensities with match between runs enabled. 7,831 unique peptide sequences were identified at 
an FDR of 1%, of which, 7,681 (98%) contained at least one cysteine residue. Peptide intensities from technical 
replicate analyses were averaged and only peptides with a minimum of 3 valid intensity values (i.e. measured 
intensity values in three biological replicate experiments) in the hydroxylamine treated set were taken forward 
for further analysis (4,877 free cysteine containing peptides from 2430 protein groups). Missing values were 
imputed for control purifications (minus hydroxylamine set) using Perseus so that statistical analysis of the data 
could be performed. This was necessary because often palmitoylated peptides were robustly identified in the plus 
hydroxylamine set but were below the limit of detection in the minus hydroxylamine set resulting in missing 
intensity values. 1,098 palmitoylation sites were significantly enriched (t-testing with a Permutation based FDR 
of 0.05, S0 = 1) in the plus hydroxylamine versus control sets (Fig. 2a). An additional magnitude of enrichment 
filter (average ratio plus/minus hydroxylamine >3) was applied to the data and redundant site quantifications 
were removed leaving a final set of 906 palmitoylation sites mapping to 641 protein groups (Tables 1 and S1). The 
average fold enrichment in this final set was 33.9 with a median fold enrichment of 10.2. As palmitoylation sites 
identified using this workflow are inferred by their relative enrichment in hydroxylamine treated versus control 
samples (same as protein level ABE) and not directly identified, sites chosen for functional experiments should 
be validated using orthogonal methods.
Properties of a site-specific brain palmitoyl-proteome. We began by testing whether this final 
set of statistically enriched palmitoylation sites had features that were different from unmodified cysteine sites 
(non-enriched cysteine-containing peptides). We annotated the entire dataset for evidence of palmitoylation 
(UniProt and published proteomics datasets) and membrane association (containing transmembrane helices) and 
performed Fisher’s exact testing (benjamini Hochberg FDR 0.02) in Perseus. Statistically enriched palmitoylation 
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sites (hydroxylamine Vs control) were significantly more likely to be from proteins with previous evidence of pal-
mitoylation (8.8E-34) and to contain transmembrane domains (1.06E-88) than the background of non-enriched 
sites (Table 1). 62.3% (565/906 sites) of enriched palmitoylation sites map to proteins with previous evidence of pal-
mitoylation (previous protein level proteomic studies as well as from the literature). These sites map to 377 known 
palmitoylated proteins representing 58.8% of proteins for which we could confidently identify palmitoylation sites. 
52.4% (475/906) of palmitoylation sites are from proteins that contain transmembrane domains (transmembrane 
domain prediction and UniProt annotation) representing 47.4% (304/641) of proteins with palmitoylation sites. 
Of the set of 906 palmitoylation sites that we identified using ssABE, 11% (102 palmitoylation sites on 63 proteins) 
have previously been demonstrated to be palmitoylated at these sites (Tables 1 and S1 (Dataset 1)).
Functional annotation of 641 palmitoylated proteins using a Fisher exact test (Perseus) revealed highly sig-
nificant enrichment (Benjamini–Hochberg corrected p values) of UniProt keywords such as “Palmitate” (p 
value 9.46E-41), “Membrane” (p value 5.47E-46) compared to the non-enriched set of proteins (1,789 proteins). 
Analysis of GO term enrichment in the same set of 641 palmitoylated proteins compared to the mouse brain 
proteome24 using PANTHER reveal enrichment of terms such as “G-protein coupled receptor signaling pathway”, 
“Ion Transport, “Synaptic transmission” and “Glutamate receptor signaling pathway” compared to the mouse 
brain proteome (Table 2). The most enriched KEGG pathways included Neuroactive ligand-receptor interac-
tion, Calcium signaling pathway, Long-term depression, and Long-term potentiation. Comparison of the brain 
Figure 1. Schematic representation of the ssABE workflow. Protein samples are (1) reduced and alkylated 
and transferred to a filter-based centrifugal unit in which the following steps are performed; (2) rapid removal 
of reagents, (3) release of palmitoyl groups from proteins by hydroxylamine treatment at neutral pH and 
concomitant biotinylation of these newly “free” cysteine residues with a TCEP-cleavable biotin (HPDP-biotin) 
(4) rapid removal of reagents, followed by (5) digestion of proteins into peptides. (6) Biotinylated peptides 
are captured on Streptavidin agarose beads, washed and eluted (using TCEP) as free cysteine-containing 
peptides and (7) identified and quantified by LC-MS/MS analysis. Quantitative enrichment of peptides in +/− 
hydroxylamine treated samples allows identification of previously palmitoylated peptides. Palmitoylation sites 
are localized in peptide sequences by the presence of free (non-alkylated) cysteine residues.
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Figure 2. Identification of palmitoylation sites by analysis of peptide enrichment in +/− hydroxylamine treated 
samples. (a) Six biological replicates (2 technical replicates for each) each for +/− hydroxylamine treatments 
were used for label free quantification. Data points in red are significantly enriched (0.05 permutation-
based FDR) in the hydroxylamine treated compared to the control set. (b) Putative palmitoylation sites were 
annotated with data from UniProt to find potential false positives. 2% of sites are annotated as being involved 
in other types of thioester linkages and 6.5% are potentially involved in predicted disulfide bonds but sites for 
disulfide bonds and palmitoylation are not mutually exclusive. (c) PLP1 contains multiple sites of palmitoylation 
and disulfide bonds. 5 palmitoylation sites were significantly enriched by ssABE whilst peptides bearing cysteine 
resides involved in the formation of disulfide bonds were not enriched upon treatment with hydroxylamine (d). 
(e) High coverage of multi-palmitoylated proteins such as the t-snare SNAP25 is obtained using ssABE. All 4 
known palmitoylation sites on SNAP25 were identified and multiple palmitoylation states were independently 
observed (on Cys 85, 88, 90 & 92) on a number of different peptides.
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palmitoyl-proteome dataset with previous synaptic proteome datasets25, 26 reveals that 490 palmitoylation sites 
were identified on 342 synaptic proteins, 44% of which are integral membrane proteins. This high representation 
of synaptic proteins in the palmitoyl-proteome is consistent with the important regulatory role of palmitoylation 
for synaptic ion channels, receptors and PDZ domain containing proteins27.
We annotated all putative palmitoylation sites with data from UniProt to indicate which cysteine residues are 
known or predicted to form disulfide bonds as well as those involved in other types of thioester bonds. 6.5% of 
our final set of palmitoylation sites are located on cysteine residues known to or are predicted to form disulfide 
bonds with a further 2% forming non-lipid thioester bonds (Fig. 2b). Palmitoylation and disulfide bonds are not 
mutually exclusive with respect to individual sites and there are known examples of cysteine residues that can be 
palmitoylated or form disulfide bonds28. In most cases, ssABE readily differentiated between palmitoylation and 
disulfide bonds by the quantitative enrichment of peptides in hydroxylamine treated versus control experiments. 
An example of this is illustrated in Fig. 2c. PLP1 (Myelin proteolipid protein) has six known sites of palmitoy-
lation and four cysteine residues that form two disulfide bonds in the extracellular domain between the third 
and fourth transmembrane domain. All six palmitoylation sites were identified as free cysteines upon hydrox-
ylamine treatment and peptides containing three disulfide bond forming cysteine residues were identified as 
carbamidomethylated by ssABE. All peptides containing palmitoylation sites were quantitatively and statistically 
enriched (permutation based FDR 0.05) in hydroxylamine treated versus control experiments whilst peptides 
with disulfide bond forming cysteine residues were not enriched. (Fig. 2d). Complete palmitoylation site coverage 
was also obtained for a t-SNARE involved in the regulation of neurotransmitter release, SNAP25 (Fig. 2e). This 
protein contains up to four sites of palmitoylation and peptides bearing one, two, three and four palmitoylated 
residues were identified. The ability to detect all of these forms of palmitoylated SNAP25 is particularly significant 
because differential palmitoylation of these sites has been shown to control intracellular patterning of SNAP25 
between the plasma membrane and the endosomal system29.
Membrane topology of palmitoylation sites. There was a clear enrichment for palmitoylation sites 
on membrane proteins; 52.4% (475/906 sites) of the final ssABE enriched set (by average +/− hydroxylamine 
ratio) of palmitoylation sites were in proteins with transmembrane helices. Of the total set of 641 palmitoylated 
proteins, 47.4% (304) contained at least one transmembrane helix compared to a frequency of 26% predicted for 
the entire human proteome30. We investigated the distribution of sites in proteins with increasing numbers of 
transmembrane helices (Fig. 3a). We observed that the enriched set of palmitoylation sites were more likely to 
be present on multi-membrane spanning proteins than the least enriched (+/− hydroxylamine treatment) set of 
sites. We have repeated this analyses using a recent brain proteome dataset of approx. 10,000 proteins detected in 
mouse brain tissue using LC-MS/MS24 and observed a 4.64-fold enrichment of proteins with four or more trans-
membrane helices in the palmitoyl- proteome set compared to the mouse brain proteome. Striking enrichment 
is particularly evident for proteins with 4, 7 and more than 8 transmembrane helices. Analysis of Gene Ontology 
terms associated with the set of palmitoylated proteins with 8 or more transmembrane domains revealed a strong 
Annotation/statistical enrichment Significance* # Sites # Proteins
Brain palmitoyl-proteome 906 641
Known palmitoylation sites 102 (11.3%) 63 (9.8%)
Previous evidence of palmitoylation 8.80E-34 565 (62.4%) 362 (56.5%)
Contain transmembrane domains 1.06E-88 475 (52.4%) 304 (47.4%)
Table 1. Overview and annotation of the brain palmitoyl-proteome
Functional annotation enrichment Significance
UniProt keywords
Membrane 5.74E-46
Palmitate 9.46E-41
Gene Ontology
G-protein coupled receptor signaling pathway 7.07E-29
Ion transport 6.81E-27
Synaptic transmission 4.32E-14
Glutamate receptor signaling pathway 1.65E-05
KEGG pathways
Neuroactive ligand-receptor interaction 3.55E-13
Calcium signaling pathway 2.80E-12
Long-term depression 4.35E-06
Long-term potentiation 8.30E-06
Table 2. Functional annotation of the brain palmitoyl-proteome. Enrichment of UniProt keywords, Gene 
Ontology terms and Kegg pathways in the brain palmitoyl-proteome was performed. Significance of enrichment 
was calculated by Fisher’s exact testing (benjamini Hochberg FDR 0.02).
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enrichment for proteins involved in “Transmembrane Transport” (adjP = 1.44e-35, hypergeometric test with BH 
adjustment), particularly those involved in sodium ion transport (Sodium channels), neurotransmitter transport 
(e.g. glutamate, GABA, dopamine) as well as various amino acid and small molecular transporters. Another 
over-represented set of proteins contain 7 transmembrane helices corresponding to palmitoylation of a large 
number of GPCRs; the biological process “G-protein coupled receptor activity” was significantly enriched in 
this set (adjP = 3.46e-26, hypergeometric test with Benj. Hoch. adjustment). In fact, 63 palmitoylation sites were 
identified on 42 GPCRs (as defined by the presence of the interpro domain “GPCR” characteristic of this class 
of proteins), 36 of which belong to the rhodopsin-like GPCR domain family. This domain was highly enriched 
in the set of 906 palmitoylation sites compared to non-enriched (+/− hydroxylamine) sites (Benj. Hoch. FDR 
3.3665E-29). 48% (20/42) of these GPCRs have previously been shown to be palmitoylated and 19 known palmi-
toylation sites were identified. Next, we looked to see if any patterns were evident in terms of the topology of pal-
mitoylation of GPCRs and found that the majority (88%) GPCRs had at least one palmitoylation site N-terminal 
to their last transmembrane domain, confirming the trend observed form numerous studies of individual GPCR 
palmitoylation (Figure S1). Some GPCR’s have additional palmitoylation sites but they all occur after the third 
transmembrane domain. Palmitoylated proteins with four transmembrane helices were enriched for “potassium 
ion transmembrane transport” e.g. voltage gated potassium channels (Benj. Hoch. FDR 8.45e-06) and ion gated 
channel activity (Benj. Hoch. FDR 1.52e-14), examples of which include GABA and Glutamate receptors. Finally, 
the enrichment of proteins with four transmembrane helices can also be accounted for by the presence of several 
ZDHHC PATs which are themselves palmitoylated.
We next investigated the proximity of palmitoylation sites to transmembrane helices in proteins. We measured 
the distance between palmitoylation sites and the nearest transmembrane helix (first or last residue of the mem-
brane spanning domain) and plotted the frequency of palmitoylation sites at increasing intervals from transmem-
brane domains (Fig. 3b). The proximity between sites and transmembrane domains clearly segregates those sites 
that are identified as palmitoylated and those that are not by ssABE. The most frequent position of palmitoylation 
Figure 3. Occurrence and topology of palmitoylation sites in transmembrane proteins. (a) The frequency of 
transmembrane helices in proteins for which we identified palmitoylation sites was compared to that occurring 
in the set of “least enriched” sites identified by the ssABE method. In general, palmitoylation sites occurred more 
frequently in multi-membrane spanning proteins with striking enrichment for proteins with 4, 7 and more than 
8 transmembrane helices. (b) The proximity of palmitoylation sites to transmembrane helices was compared to 
an equivalent number of the “least enriched” sites identified by the ssABE method. Two distinct distributions are 
observed with palmitoylation sites most frequently located approximately 15 residues from a transmembrane helix 
and the “least enriched” sites being most frequent over 400 residues from a transmembrane helix. The position of 
palmitoylation sites and the set of “least enriched” sites identified by ssABE relative to protein length was compared 
for transmembrane proteins in (c) and soluble proteins in (d). Relative positions are expressed as a percentage of 
the protein length in residues. Palmitoylation sites in transmembrane proteins are most frequently located in the 
first 10% of proteins (N-terminus) or in the last 20% (C-terminus). Palmitoylated soluble proteins exhibit a different 
profile with the most frequent position of palmitoylation sites located in the first 10% of the proteins (extreme 
N-terminus) but without the C-terminal distribution spike observed for palmitoylated transmembrane proteins.
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sites is 15 residues from a transmembrane domain interface and 74% of all palmitoylation sites identified on 
transmembrane proteins were within 50 residues of a transmembrane domain. In order to investigate whether 
palmitoylation of integral membrane proteins and soluble proteins differ in terms of their topological location we 
plotted the relative position of palmitoylation sites and the least enriched sites (by ssABE) in terms of their relative 
position expressed as a percentage of protein length (Fig. 3c,d). Palmitoylation sites in membrane proteins are 
most frequent at their extreme N-terminus and also their C-terminus, a characteristic feature of GPCRs. Soluble 
proteins are most frequently palmitoylated at their N-terminus consistent with that observed for well-known 
soluble proteins such as PSD-95 and Grip1.
Concurrent identification of palmitoylation and phosphorylation sites. The relationship between 
different post-translational modifications on the same protein is often poorly understood but recent exam-
ples of regulatory crosstalk between palmitoylation and phosphorylation31–33 prompted analysis of our brain 
palmitoyl-proteome data with the aim of identifying peptides that were co-modified. Raw data was analyzed 
using MaxQuant with ser/thr/tyr phosphorylation set as a variable modification. 156 PSMs were identified 
that contained both potential palmitoylation and phosphorylation sites in the same spectrum with a posterior 
error probability cut off of 0.01 (Table S2 (Dataset 2)). Of these, 46 identified palmitoylation sites (Table S2 and 
Figure S2) mapped to proteins that we had already identified in the brain palmitoyl-proteome and 35 identified 
palmitoylation sites that we had already identified in the brain palmitoyl proteome, i.e. independently identified 
as significantly enriched palmitoylation sites from the same raw data files. An additional 4 sites that were iden-
tified as potential palmitoylation sites but were not statistically enriched in +/− hydroxylamine treatment were 
also identified on phosphopeptides in this re-analysis of the data. Of the 46 phosphorylation sites on peptides 
co-modified with palmitoylation, 23 have been previously reported (PhosphoSitePlus).
Examples of two of these cases are illustrated in Fig. 4. We identified a peptide mapping to the c-terminal 
cytoplasmic domain of the Cannabinoid receptor 1 that identified Cys416 as palmitoylated (Fig. 4a). Mutation 
of this site functionally impairs membrane targeting and signaling of the receptor by reducing recruitment at 
both plasma membrane and lipid rafts and decoupling the receptor from G-proteins34. This same peptide also 
identified two phosphorylation sites (Ser426 and Ser430) which when phosphorylated by a G-protein-coupled 
receptor kinase (GRK) results in receptor desensitization and regulates an acute response to, tolerance to, and 
dependence on cannabinoids35. An additional novel palmitoylation site was identified at Cys432; palmitoylation 
at both sites could form a double loop topology in the cytoplasmic domain which could create a protein interac-
tion site or could alter the conformation of the protein to regulate phosphorylation at Ser426 and S430. The inter-
play between phosphorylation and palmitoylation at these sites is not fully understood but given their individual 
functions and proximity, it is possible that they interact to form a regulatory module to control receptor activity. 
We identified a similar arrangement of palmitoylation and phosphorylation sites for the Glutamate receptor, 
NMDA2B subunit (Fig. 4b). These receptors are palmitoylated at two distinct sites36 and we have identified a 
known site in cluster 1 (Cys871) which regulates the phosphorylation of nearby tyrosine phosphorylation sites 
to enhance stable surface expression of the receptor. We identified two additional known phosphorylation sites 
(Ser882 and Ser886)36–39 on the peptide identifying Cys871 as palmitoylated. The function of these two phospho-
rylation sites is unknown but proximity to Cys871 may allow a functional interaction between phosphorylation 
and palmitoylation at these sites.
Potential palmitoylation motifs. A major motivation for developing a method that permits large-scale anal-
ysis of palmitoylation sites is the ability to explore sequence features and motifs in the vicinity of this modification 
and to improve prediction of palmitoylation sites. Motif-x was used to identify overrepresented motifs in 
sequences surrounding palmitoylation sites (+/− 6 residues) compared to the mouse proteome. Although 
this approach would be akin to taking a collection of phosphorylation sites and looking for motifs without any 
knowledge of kinase substrate specificity, we hypothesized that the most prominent features that distinguish sites 
modified by groups of PATs might be evident. At a significance cut-off of 0.001, 9 distinct motifs were evident 
in the set of 906 palmitoylation sites (Fig. 5); dicysteine motifs and single cysteine motifs with hydrophobic res-
idues (Leucine, Isoleucine, Tryptophan and Phenylalanine) at specific positions relative to palmitoylation sites. 
Annotation of these different motifs with the presence or absence of transmembrane helices in proteins associated 
with them revealed that some motifs (FxCC) were almost exclusively in transmembrane proteins whilst others 
(IxxxC) were predominantly in soluble proteins. Repetition of this analysis on sites within transmembrane pro-
teins and soluble proteins separately, revealed that the original 9 motifs segregated into two groups on the basis 
of the occurrence of transmembrane domains in associated proteins. Palmitoylation sites on transmembrane 
proteins were enriched for di-cysteine motifs with CC* and C*C (*denotes palmitoylation site) accounting for 
25% of all sites in this category and the motif FxCC having the highest enrichment in ssABE experiments, high-
est occurrence of transmembrane domains and the highest content of previously known palmitoylated proteins 
(Fig. 5). Soluble proteins only contained motifs containing single cysteines and hydrophobic amino acids within 
4 residues and the most common motifs being CxxL and CF.
Palmitoylation of palmitoyl acyltransferases. We identified 21 sites of palmitoylation on 10 DHHC 
domain-containing palmitoyl-acyltransferases (Fig. 6) representing 43% of all known palmitoyl-acyltransferases1 
and likely the majority of those expressed in the brain. We identified the S-palmitoyl cysteine intermediate that 
occurs in the active site cysteine residue in the “DHHC*” domain for 4 PATs (ZDHHC5, 9, 17 &18). Whilst, 
active site palmitoylation has been directly detected in experiments targeted to individual PATs40, our approach 
facilitates unbiased site-specific detection of active site palmitoylation of PATs by mass spectrometry. PAT active 
sites are rapidly autopalmitoylated and then either the palmitoyl group is transferred to substrate proteins or it 
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is hydrolyzed to release free fatty acid41. In either case, active site palmitoylation is continuously turned over but 
the enzyme exists in a permanently palmitoylated state in the absence of substrates41. ZDHHC5 regulates AMPA 
receptor trafficking by palmitoylation of the glutamate receptor interacting protein, GRIP142, membrane associ-
ation of BK channel STREX variant43, is regulated by induction of neuronal differentiation44, interacts with PDZ 
domain containing scaffolding proteins such as PSD-95 and plays a role in learning and memory45. ZDHHC17 
(Hip14) was first shown to palmitoylate huntingtin protein and regulate its trafficking a process that is affected by 
polyglutamine tract expansion in Huntington’s disease46. Since then it has been shown to regulate SNAP25/2347 
and STREX43 membrane association and its absence in knockout mice causes alterations in synaptic plasticity and 
impaired hippocampal memory formation48. ZDHHC9 palmitoylates Ras proteins49 and STREX43 and the least 
Figure 4. Concurrent identification of palmitoylation and phosphorylation sites. Examples of potential 
interplay between palmitoylation and phosphorylation are shown in (a) Cannabinoid receptor 1, (b), Glutamate 
receptor, NMDA 2B (c) associated fragmentation spectra shown in (d,e), respectively. 46 phosphorylated (with 
23 known sites of phosphorylation) and palmitoylated peptides (co-modified) were identified and these sites of 
palmitoylation were also independently identified in the brain palmitoyl proteome.
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well characterized is ZDHHC18 which is capable of palmitoylating H-Ras and Lck1. These four PATs for which we 
have detected active site palmitoylation are likely to represent the most abundant or active members of this enzyme 
family in the brain and include two which have been shown to be very important for neuronal specific processes.
In addition, we have also identified 17 sites of palmitoylation located C-terminal to the active site in several 
PATs with a site in 5 enzymes (ZDHHC5, 8, 16, 17 & 20) clustered to a single conserved cysteine in a “GCxxN” 
motif (Fig. 6c). A recent study identified a high confidence palmitoylation site in this region of ZDHHC519 and 
we have now extended and experimentally confirmed that this conserved site is palmitoylated in four other family 
members. In ZDHHC5 and ZDHHC8, we detect additional sites C-terminal to this, with 8 mapping to the pre-
viously described CCX7–13C*(S/T) motif, where C* is palmitoylated19. In order to confirm that PATs are indeed 
multiply palmitoylated in vivo, we performed a PEG-switch assay50 using a mouse brain extract and found that 
DHHC5 protein exists in a predominantly palmitoylated form with evidence for multiply palmitoylated states 
(Fig. 6e) as evidenced by multiple hydroxylamine dependent band shifts. The functional consequences of these 
additional palmitoylation sites are unknown but they may modulate the conformation of the cytoplasmic tail of 
these PATs to create binding sites for substrates or indeed regulatory proteins.
Figure 5. Palmitoylation site motifs distinguish palmitoylation of transmembrane and soluble proteins.  
(a,b) Motif-x was used to identify significantly enriched sequence motifs in sequences +/− 6 residues in the set 
of 906 enriched palmitoylation sites compared to the mouse proteome. Re-analysis of palmitoylation sites from 
proteins with transmembrane helices and those that do not (soluble proteins) revealed that these two types of 
palmitoylated proteins have distinct enriched sequence motifs with transmembrane proteins containing mainly 
di-cysteine containing motifs and soluble proteins containing single cysteine residues and leucine, tryptophan, 
phenylalanine and isoleucine and specific positions.
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Conclusions
We have developed a workflow that builds upon standard acyl-biotin exchange assays to permit large scale anal-
ysis of palmitoylation sites. This has enabled the first global analysis of the brain palmitoyl-proteome with pal-
mitoylation site resolution and has allowed us to investigate sequence features surrounding palmitoylation sites. 
We find that integral membrane proteins and soluble proteins are palmitoylated but that integral membrane 
proteins are disproportionately enriched given that they contribute over half of the dataset but represent just over 
a quarter of the proteome. Differences in the topology and potential palmitoylation motifs suggest that different 
PATs may modify different sets of proteins and that palmitoylation may have diverse functional consequences. 
Clearly, palmitoylation of soluble proteins aids membrane tethering whilst palmitoylation of integral membrane 
proteins may have a more subtle effect. Perhaps, tethering of intracellular loops can regulate integral membrane 
function by changing accessibility of protein interactors or enzymes mediating other PTMs. Palmitoylation near 
transmembrane helices alters protein structure by causing tilting of membrane spanning domains and to regulate 
Figure 6. Palmitoylation of protein acyltransferases. (a) 21 palmitoylation sites were identified on 10 
(starred) out of 23 known DHHC-domain containing protein acyltransferases. (b) Relative intensities of 
peptides identifying these modifications are shown in +/− hydroxylamine treated sets. All detected potential 
palmitoylation sites for PATs were significantly enriched over control purifications in ssABE experiments.  
(c,d) Palmitoylated active site intermediates were detected for 4 PATs (starred red in (a)) and additional non-
active site palmitoylation was found for 9 PATs, a subset of which was in a conserved “GC*xxN” motif in 5 PATs 
(c). (e) PEG switch assay of endogenous mouse brain DHHC5. Band shifts corresponding to the addition of 
5 kDa PEG groups to sites of palmitoylation sensitive to hydroxylamine HA) treatment allow the detection of 
at least two palmitoylated forms of DHHC5 thus confirming that it is also palmitoylated at sites other than the 
active site cysteine residue. An uncropped image of this PEG switch blot is presented in Figure S3.
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protein sorting to lipid rafts. As well as allowing questions to be asked about the exact positioning of palmi-
toylation sites, ssABE permitted the identification of peptides co-modified by both palmitoylation and phos-
phorylation. Given the interplay of these two modifications that has been established for a few examples, the 
identification of co-modified peptides using ssABE should allow this phenomenon to be investigated in more 
detail. The ability to identify and quantify active site palmitoylation of PATs using ssABE was unexpected but adds 
yet another dimension to the approach. This permits the most active/abundant PATs to be identified, giving a first 
step toward narrowing down the list of PATs that can modify substrates in that sample. Finally, given that ssABE is 
quantitative, it could be used in perturbation experiments to quantify differential palmitoylation with site-specific 
resolution. The combination of ssABE with perturbations or stimulation paradigms offers the potential to dissect 
the role of palmitoylation associated with specific biological questions and the opportunity to expand our under-
standing of this class of post-translational modification.
Experimental procedures
Protein extraction and reduction and alkylation. Mouse forebrain tissue was solubilized in the follow-
ing extraction buffer (4% SDS, 0.1 M Tris pH 8.5, 2 ug/μl aprotinin/leupeptin, 0.5 mM PMSF, 20 μM ZnCl, 5 mM 
EDTA, 50 mM TCEP, 25 mM iodoacetamide). 8.5 ml of extraction buffer was used per forebrain. Samples were 
homogenized 25 times dounce homogenizer and heated at 70 °C for 20 min and DNA was sheared by passing the 
extract through fine gauge needle 10 times. Insoluble material was removed by centrifugation and the supernatant 
was retained. Additional iodoacetamide was added to bring the concentration to 50 mM and urea was added to 
a final concentration of 8 M and was incubated in the dark for 3 hours at room temperature to allow alkylation to 
proceed to completion.
Sample clean-up. Two aliquots (2 mg each) were transferred to two prewashed (8 M Urea/100 mM Tris pH 8) 
amicon ultra 30 kD MWCO spin columns (Millipore) and were centrifuged to begin buffer exchange. The sam-
ples were buffer exchanged with the addition of 2 mL 8 M Urea/100 mM Tris pH 7.4 and centrifugation, five times.
Acyl-biotin exchange and sample clean-up. HPDP-biotin solubilized in 20 μl N,N-dimethylforamide 
was added to the sample in the upper chamber of the amicon ultra unit to achieve a final concentration of 1 mM 
biotin. Hydroxylamine pH 7.4 was added to the +HA sample to a final concentration of 0.7 M and 100 mM 
Tris pH 7.4 was added to the control (−HA) sample. Hydroxylamine treatment and biotin labelling of newly 
released free cysteine residues was allowed to proceed for 1 hr at room temperature and then samples were buffer 
exchanged with the addition of 2 mL 8 M Urea/100 mM Tris pH7.4 and centrifugation, four times and a final wash 
with 2 mL 8 M Urea/100 mM ammonium bicarbonate.
Tryptic digestion and peptide collection. The samples were diluted to a final concentration of 1 M Urea 
and were digested with Trypsin Gold (Promega) at an enzyme substrate ratio of 1:50 for 3 hours at 37 °C. Peptides 
were collected from the upper chamber and the chamber membrane was washed with 2 ml 2× LB buffer (100 mM 
Tris, 300 mM NaCl, 10 mM EDTA, pH 7.4). After centrifugation the collected peptides were pooled and stored 
overnight at −20 °C.
Purification of biotinylated peptides. 100 μl bed volume of streptavidin-agarose resin was washed with 
LB buffer (3 × 1 ml) and was added to the peptide samples and incubated for 1 hr at room temp. The superna-
tant was washed by gentle centrifugation and the resin was washed with 10 ml of wash buffer (0.1% SDS, 0.2% 
Tx-100, 50 mM Tris pH 7.4, 150 mM NaCl), incubated for 10 min and repeated. The resin was transferred to a 
mini-column and washed 2 × 10 ml wash buffer (2 M Urea/100 mM Tris pH 7.4) using a syringe, then with 2 ml 
H2O. Peptides were eluted by the addition of 50 μl 10 mM TCEP and incubation for 10 min at 37 °C, this was 
repeated and eluates were combined and acidified by the addition of formic acid.
LC-MS/MS analysis. Peptides from purifications were split and each analyzed by 2 replicate LC-MS/MS 
analyses. Samples were analyzed using an Ultimate 3000 RSLC Nano LC System (Dionex) coupled to an LTQ 
Orbitrap Velos hybrid mass spectrometer (Thermo Scientific) equipped with an Easy-Spray (Thermo Scientific) 
ion source. Peptides were desalted on-line using a capillary trap column (Acclaim Pepmap100, 100 μm, 
75 μm × 2 cm, C18, 5 μm (Thermo Scientific)) and then separated using 120/180 min RP gradient (4–30% ace-
tonitrile/0.1% formic acid) on an Acclaim PepMap100 RSLC C18 analytical column (2 μm, 75 μm id x 50 cm, 
(Thermo Scientific)) with a flow rate of 0.3 μl/min. The mass spectrometer was operated in standard data depend-
ent acquisition mode controlled by Xcalibur 2.2. The instrument was operated with a cycle of one MS (in the 
Orbitrap) acquired at a resolution of 60,000 at m/z 400, with the top 15 most abundant multiply-charged (2 + and 
higher) ions in a given chromatographic window were subjected to CID fragmentation in the linear ion trap. An 
FTMS target value of 1e6 and an ion trap MSn target value of 10000 were used. Dynamic exclusion was enabled 
with a repeat duration of 30 s with an exclusion list of 500 and exclusion duration of 60 s. Lock mass of 401.922 
was enabled for all experiments.
Mass Spectrometry data analysis. Data was analyzed using MaxQuant version 1.4.1.223. MaxQuant 
processed data was searched against a UniProt (downloaded October 2013) mouse sequence database (52654 
sequences) using the following search parameters: trypsin with a maximum of 2 missed cleavages, 7 ppm for MS 
mass tolerance, 0.5 Da for MS/MS mass tolerance, with acetyl (Protein N-term) and oxidation (M) as variable 
modifications and carbamidomethyl (C) as a fixed modification. Palmitoylation sites were reported and localized 
in peptide sequences by the use of a loss of 57.02146 (i.e. unmodified cysteine) as only those cysteines targeted 
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by acyl-biotin exchange should be unmodified, all other cysteines should be alkylated. A protein FDR of 0.01 and 
a peptide FDR of 0.01 were used for identification level cut offs. Class I palmitoylation sites were defined with a 
localization probability of >0.75 and a score difference of >5. Match between runs with a 2 minute retention time 
window was enabled and peptide intensity values calculated by MaxQuant were used to quantify enrichment of 
peptides in +/− hydroxylamine treated samples (6 biological replicates and 2 technical replicates, each). Data was 
filtered so that at least 3 valid intensity values were present (3/6 biological replicates) in hydroxylamine treated 
samples and log2 transformed. Missing values in control experiments were imputed using Perseus (1.4.1.3) and 
two sample t-testing was performed with a permutation based FDR calculation in Perseus. Peptides enriched 
within an FDR of 0.05 with at least a 3-fold change were defined as being enriched hydroxylamine treated sam-
ples and therefore identifying peptides with putative sites of palmitoylation. Analysis of enrichment of UniProt 
keywords in the set of palmitoylated proteins compared to the non-enriched set was performed using Perseus 
with a Fisher exact test and a Benjamini-Hochberg FDR of 0.02. Analysis of GO term enrichment in the set of 
palmitoylated proteins compared to the mouse brain proteome24 was performed using a PANTHER51 overrep-
resentation test with Bonferroni correction for multiple testing. Enrichment of KEGG pathways in the same 
set of palmitoylated proteins compared to the mouse brain proteome was performed using WebGestalt52 with 
Benjamini-Hochberg correction for multiple hypothesis testing.
PEG-switch assays. PEG switch assays were performed as described50 with some minor modifications. 
Whole mouse forebrain was homogenized in 4% SDS, 50 mM Tris pH7.2 and 1 mM EDTA. Lysates were heated 
at 70 °C for 20 minutes and DNA was sheared by passing the lysates through a fine gauge needle. After cooling, 
HEPES buffer and maleimide were both added to 100 mM final concentration and samples were incubated at 
40 °C for 3 hours with shaking to block all free cysteines. Protein was precipitated with 4× volume of ice-cold 
acetone, and the pellet was washed 5 times with 80% acetone to remove any excess maleimide. Pellets were 
re-suspended in 1% SDS, 1 mM EDTA and 50 mM Tris pH 7.2 and split into +/− hydroxylamine samples. To 
the +HA sample 2 M HA pH 7.2/50 mM Tris pH 7.2 was added to a final concentration of 1 M HA, to the –HA 
sample, the same volume of 50 mM Tris pH 7.2 was added. Samples were left at room temperature for 1 hour 
with end over end rotation. Acetone precipitation of protein was performed as described above. Pellets were 
re-suspended in 1% SDS/50 mM Tris pH 7.2, and mPEG 5 kDa was added to 5 mM final concentration. Samples 
were incubated at 25 °C for 1 hour with shaking. Protein was acetone precipitated as described above. Pellets 
were re-suspended in 2.5% SDS/50 mM Tris, before western blotting using an anti-ZDHHC5 Antibody (Atlas 
Antibodies (HPA014670)).
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